Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Cara Therapeutics (CARA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 872,238
  • Shares Outstanding, K 39,290
  • Annual Sales, $ 910 K
  • Annual Income, $ -58,130 K
  • 36-Month Beta 2.90
  • Price/Sales 965.21
  • Price/Cash Flow N/A
  • Price/Book 11.60

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.46
  • Number of Estimates 5
  • High Estimate -0.40
  • Low Estimate -0.60
  • Prior Year -0.38
  • Growth Rate Est. (year over year) -21.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.88 +33.78%
on 08/27/18
24.01 -0.37%
on 09/20/18
+5.00 (+26.43%)
since 08/20/18
3-Month
15.72 +52.16%
on 06/25/18
24.01 -0.37%
on 09/20/18
+7.28 (+43.75%)
since 06/20/18
52-Week
11.11 +115.30%
on 11/03/17
24.01 -0.37%
on 09/20/18
+10.71 (+81.07%)
since 09/20/17

Most Recent Stories

More News
CBD Stocks Set to Explode

HENDERSON, NV / ACCESSWIRE / September 19, 2018 / It's just a matter of time before medical marijuana will become legal in all 50 states. It's not surprising when you consider a recent poll shows 93%...

CARA : 23.92 (+7.75%)
GWPH : 170.10 (+10.71%)
CIIX : 0.6752 (+27.40%)
ZYNE : 8.01 (+1.91%)
Intriguing Cannabis and Biotech Firms

HENDERSON, NV/ ACCESSWIRE / September 14, 2018 / A fascinating biotech firm DCTH (Delcath Systems, Inc.), has a very intriguing treatment for liver cancer. The company has initiated a global Phase 3 clinical...

CARA : 23.92 (+7.75%)
ACBFF : 9.4900 (+12.44%)
APHQF : 15.4500 (+3.07%)
INSY : 9.45 (+3.85%)
DCTH : 7.2100 (-16.94%)
Major Stem Cell Breakthroughs Giving Investors Big Opportunity

HENDERSON, NV / ACCESSWIRE / September 14, 2018 / Last week, Sangamo Therapeutics became the first company to edit a patient's DNA inside the body, usually the process is done outside the body. This is...

SGMO : 15.95 (+3.91%)
CARA : 23.92 (+7.75%)
GERN : 5.50 (-0.18%)
The Zacks Analyst Blog Highlights: Diageo, Constellation Brands, Cara, Cronos and GW

The Zacks Analyst Blog Highlights: Diageo, Constellation Brands, Cara, Cronos and GW

CRON : 13.75 (+8.35%)
CARA : 23.92 (+7.75%)
STZ : 218.57 (+1.58%)
GWPH : 170.10 (+10.71%)
DEO : 140.85 (+2.41%)
ETFs & Stocks to Tap Marijuana Boom

Investors seeking to tap the ongoing green rush may consider these ETFs and stocks.

HEINY : 48.1000 (+1.42%)
CRON : 13.75 (+8.35%)
CARA : 23.92 (+7.75%)
ACT : 27.29 (+3.21%)
STZ : 218.57 (+1.58%)
GWPH : 170.10 (+10.71%)
MJ : 43.01 (+4.37%)
CGC : 52.40 (+6.18%)
DEO : 140.85 (+2.41%)
ETFs & Stocks to Tap Marijuana Boom

Investors seeking to tap the ongoing green rush may consider these ETFs and stocks.

HEINY : 48.1000 (+1.42%)
CRON : 13.75 (+8.35%)
CARA : 23.92 (+7.75%)
ACT : 27.29 (+3.21%)
STZ : 218.57 (+1.58%)
GWPH : 170.10 (+10.71%)
MJ : 43.01 (+4.37%)
CGC : 52.40 (+6.18%)
DEO : 140.85 (+2.41%)
Cara Therapeutics to Present at the 27th European Academy of Dermatology & Venereology Congress

Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral...

CARA : 23.92 (+7.75%)
Cara Therapeutic Rises 3.91% on Heavy Volume: Watch For Potential Pullback

Cara Therapeutic (NASDAQ:CARA) traded in a range yesterday that spanned from a low of $18.65 to a high of $19.50. Yesterday, the shares gained 3.9%, which took the trading range above the 3-day high...

CARA : 23.92 (+7.75%)
Analysis: Positioning to Benefit within C&J Energy Services, LivePerson, Kadmon, Cara Therapeutics, CorMedix, and Second Sight Medical Products -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of C&J Energy Services, Inc. (NYSE:CJ),...

CARA : 23.92 (+7.75%)
EYES : 1.78 (+1.71%)
CJ : 21.88 (+0.32%)
KDMN : 3.35 (+0.30%)
CRMD : 0.62 (+0.93%)
LPSN : 26.60 (+1.92%)
Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates

Cara (CARA) delivered earnings and revenue surprises of -4.00% and 359.84%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

CARA : 23.92 (+7.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade CARA with:

Business Summary

Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States.

See More

Key Turning Points

2nd Resistance Point 23.93
1st Resistance Point 23.06
Last Price 23.92
1st Support Level 21.65
2nd Support Level 21.10

See More

52-Week High 24.01
Last Price 23.92
Fibonacci 61.8% 19.08
Fibonacci 50% 17.56
Fibonacci 38.2% 16.04
52-Week Low 11.11

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar